Pharmacokinetics and pharmacodynamics of artesunate and dihydroartemisinin following oral treatment in pregnant women with asymptomatic Plasmodium falciparum infections in Kinshasa DRC

Table 4 DHA noncompartmental pharmacokinetic data in pregnant, postpartum, and non-pregnant women with Plasmodium falciparum infection.

	Antepartum vs. Postpartum*		Antepartum vs. Non-pregnant controls†		Postpartum vs. Non-pregnant controls†
Parameters	Estimate (90% CI)	P-value	Estimate (90% CI)	P-value	Estimate (90% CI)	P-value
C_max (ng/mL)	1.06 (0.87, 1.30)	0.62	0.81 (0.63, 1.03)	0.15	0.77 (0.61, 0.98)	0.070
T_max (h)	0.99 (0.74, 1.33)	0.95	0.90 (0.66, 1.23)	0.58	0.89 (0.67, 1.17)	0.47
AUC_all (ng*h/mL)	0.87 (0.77, 0.98)	0.064	0.68 (0.57, 0.81)	0.0004	0.78 (0.66, 0.92)	0.014
AUC_free (ng*h/mL)	0.99 (0.85, 1.15)	0.92	0.78 (0.63, 0.95)	0.039	0.78 (0.65, 0.95)	0.038
CL/F (L/h)	1.21 (1.09, 1.33)‡	0.0075	1.48 (1.24, 1.76)	0.0004	1.29 (1.09, 1.52)	0.014
CL/F (L/kg/h)	1.16 (1.03, 1.29)‡	0.040	1.36 (1.18, 1.57)	0.0008	1.24 (1.07, 1.44)	0.016
T½ (h)	0.84 (0.75, 0.96)	0.028	0.86 (0.72, 1.02)	0.15	1.03 (0.86, 1.22)	0.80
Vd/F (L)	0.97 (0.83, 1.14)	0.74	1.26 (1.00, 1.60)	0.097	1.32 (1.04, 1.67)	0.056
Vd/F (L/kg)	0.95 (0.81, 1.12)	0.61	1.18 (0.96, 1.44)	0.19	1.26 (1.02, 1.56)	0.073
FF	1.14 (1.05, 1.24)	0.013	1.15 (1.02, 1.28)	0.051	1.01 (0.89, 1.14)	0.92

Relative estimates (90% CIs) and parametric tests for group comparisons
* Geometric mean antepartum:postpartum ratio and 90% CI; 1-sample t-test on logged ratios.
† Ratio of geometric means and 90% CI; 2-sample t-test on logged data
‡ Mean antepartum:postpartum ratio and 90% CI; 1-sample t-test on ratio

ISSN: 1475-2875